1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
David Goodloe
David Goodloe
Articles (727) 

Sarepta Shares Tumble Following FDA Committee's Decision

Panel does not recommend approval of muscular dystrophy treatment drug

April 26, 2016 | About:

On the news that a Food and Drug Administration advisory committee had declined to recommend the approval of eteplirsen, an experimental drug designed to treat Duchenne muscular dystrophy (DMD), the price of shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell by nearly half in early trading Tuesday.

The committee’s vote Monday night was 7-3 against recommending approval with three abstentions.

“The FDA is not obliged to follow the advice of its advisory panels,” Reuters reported, “but typically does so."

Sarepta, a Cambridge, Massachusetts-based medical research and drug development company, sold for $8.58 per share, Sarepta’s lowest share price since August 2012, when markets opened Tuesday. On April 18, shares of Sarepta sold for $22.43 apiece.

On Oct. 7, 2013, the stock sold for $53.81 per share.

740345517.png

Duchenne muscular dystrophy is a rare genetic degenerative muscle disease that is typically found in one boy in 3,500 to 5,000 worldwide. Both sexes can carry it, but females are seldom affected by it. An estimated 9,000 to 12,000 Americans suffer from the disease.

It is caused by a mutation in the gene dystrophin, an important element in muscle tissue. Eteplirsen is concentrated on mutations in a region linked to about one in eight cases.

Steven Cohen (Trades, Portfolio) is Sarepta’s leading shareholder among the gurus with a stake of 2,375,700 shares. The stake is 5.2% of Sarepta’s outstanding shares and 0.76% of Cohen’s total assets. Cohen raised his stake by nearly 161% in the fourth quarter.

Sarepta has a P/B of 2.3 and a P/S of 325.3. GuruFocus gives Sarepta a Financial Strength rating of 3/10 and a Profitability and Growth rating of 1/10.

The stock’s price rebounded by the close of trading Tuesday, selling for $11.02 per share.

To view the gurus' latest stock picks, visit the Real Time Stock Picks page. Not a premium member of GuruFocus? Try it free for seven days.

About the author:

David Goodloe
I'm a journalist by training. I grew up in Arkansas and earned my B.A. at the University of Arkansas. I earned my master's degree at the University of North Texas. My background includes stints at newspapers in Arkansas and Texas and teaching news writing and news editing to students at the University of Oklahoma and Richland College here in Dallas. I'm a writer/editor at GuruFocus.

Rating: 5.0/5 (1 vote)

Voters:

Comments

Please leave your comment:


GuruFocus has detected 3 Warning Signs with Sarepta Therapeutics Inc $SRPT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Performances of the stocks mentioned by David Goodloe


User Generated Screeners


DANGORDONBOOK VAL GR 4-29-17
dvnrravinidhi_ev_ebitda
Roger SteraHEALTHY GROWTH
Roger SteraSmall Quality
Roger SteraEPS GROWTH 4-28-17
matt.bakerHEALTHY GROWTH
coybarnesSmall Quality
Roger SteraNetNets
Roger SteraWalter Schloss Screen
Roger SteraFast Growers
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK